만성 신장병(CKD) 시장 규모, 점유율, 성장 분석 : 진단별, 치료법별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Chronic Kidney Disease Market size was valued at USD 16.93 Billion in 2024 and is poised to grow from USD 20.34 Billion in 2025 to USD 88.03 Billion by 2033, growing at a CAGR of 20.1% during the forecast period (2026-2033).

The market for chronic kidney disease (CKD) is experiencing growth due to the increasing prevalence of diabetes and hypertension, which are primary contributors to CKD. The global aging population further exacerbates this issue, as kidney function typically declines with age. Heightened awareness among patients and healthcare professionals regarding CKD leads to earlier detection and diagnosis, ultimately driving demand for therapeutic drugs, intervention strategies, and advanced technological treatments. This ongoing trend underscores the necessity for effective management solutions to address the growing burden of CKD, creating significant opportunities for market players. As healthcare systems adapt to these challenges, the market is poised for continued expansion, emphasizing the importance of innovation and accessibility in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is significantly influenced by the increasing prevalence of diabetes and hypertension, both of which are primary contributors to kidney damage. As the populations affected by these chronic conditions continue to grow, there will be a corresponding rise in the demand for effective treatments. This increasing incidence of both diabetes and high blood pressure will lead to a higher number of individuals diagnosed with chronic kidney disease, thereby driving the market forward. The link between these chronic illnesses and kidney health highlights the necessity for advanced therapies and interventions to manage and address the escalating health challenges.

Restraints in the Global Chronic Kidney Disease Market

The Global Chronic Kidney Disease market faces significant challenges due to the high costs associated with managing advanced stages of the disease. Treatments such as dialysis and kidney transplants entail substantial financial investments, which can create a considerable burden for patients, particularly in regions with limited healthcare coverage. This financial strain not only hinders patient access to necessary care but also impacts the overall budgets of national health systems. Consequently, addressing these economic constraints is crucial for improving patient outcomes and ensuring equitable access to treatment options in the realm of chronic kidney disease management.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant trend towards early diagnosis and proactive intervention, shifting the focus from late-stage treatment to preventive measures. This paradigm shift emphasizes the importance of screening high-risk populations to facilitate timely identification of the disease. As healthcare systems evolve, there is a rising demand for innovative therapeutic solutions designed to slow disease progression and improve patient outcomes, ideally before the need for dialysis arises. This proactive approach not only enhances quality of life for patients but also reduces the overall burden on healthcare resources, highlighting a transformative perspective in chronic kidney disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Test
  • Serum Creatinine Test
  • Glomerular Filtration Rate (GFR) Test
  • Blood Urea Nitrogen (BUN) Test
  • Electrolyte Tests
• Urine Test
  • Urinalysis
  • 24-hour Urine Collection
  • Urine Protein Test
  • Urine Albumin-To-Creatinine Ratio (ACR)
• Imaging Test
  • Ultrasound
  • CT Scan
  • MRI
  • X-ray
• Kidney Biopsy
  • Percutaneous Kidney Biopsy
  • Open Kidney Biopsy
  • Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vera Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProKidney (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renalytix Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations